“A Matching-Adjusted Indirect Comparison of the Efficacy of Bimekizumab and Guselkumab at 52 weeks for the Treatment of Psoriatic Arthritis” (2024) SKIN The Journal of Cutaneous Medicine, 8(1), p. s312. doi:10.25251/skin.8.supp.312.